Fulcrum Therapeutics (FULC) Operating Leases (2022 - 2026)

Fulcrum Therapeutics (FULC) has 5 years of Operating Leases data on file, last reported at $3.4 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $3.4 million, down 41.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.4 million (down 41.94% YoY), and the FY2025 annual result was $4.0 million, down 37.31% from the prior year.
• Operating Leases slipped to $3.4 million in Q1 2026 per FULC's latest filing, from $4.0 million in the prior quarter.
• Over five years, Operating Leases peaked at $12.8 million in Q1 2022 and troughed at $3.4 million in Q1 2026.
• A 5-year average of $8.1 million and a median of $8.1 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2024 and 2026: Operating Leases slipped 20.05% in 2024, then plunged 41.94% in 2026.
• A 5-year view of Operating Leases shows it stood at $10.8 million in 2022, then retreated by 20.26% to $8.6 million in 2023, then retreated by 25.33% to $6.4 million in 2024, then tumbled by 37.31% to $4.0 million in 2025, then slipped by 15.67% to $3.4 million in 2026.
• Business Quant data shows FULC's Operating Leases at $3.4 million in Q1 2026, $4.0 million in Q4 2025, and $4.7 million in Q3 2025.